- Home
- IFRX vs PVL Comparison
IFRX vs PVL Comparison
Compare IFRX & PVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- PVL
- Stock Information
- Founded
- IFRX 2007
- PVL 2011
- Country
- IFRX Germany
- PVL United States
- Employees
- IFRX N/A
- PVL N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- PVL Oil & Gas Production
- Sector
- IFRX Health Care
- PVL Energy
- Exchange
- IFRX Nasdaq
- PVL Nasdaq
- Market Cap
- IFRX 56.4M
- PVL 61.4M
- IPO Year
- IFRX 2017
- PVL N/A
- Fundamental
- Price
- IFRX $0.79
- PVL $1.82
- Analyst Decision
- IFRX Strong Buy
- PVL
- Analyst Count
- IFRX 4
- PVL 0
- Target Price
- IFRX $7.75
- PVL N/A
- AVG Volume (30 Days)
- IFRX 282.5K
- PVL 113.2K
- Earning Date
- IFRX 08-07-2025
- PVL 01-01-0001
- Dividend Yield
- IFRX N/A
- PVL 5.17%
- EPS Growth
- IFRX N/A
- PVL N/A
- EPS
- IFRX N/A
- PVL 0.09
- Revenue
- IFRX $140,242.00
- PVL $4,344,009.00
- Revenue This Year
- IFRX N/A
- PVL N/A
- Revenue Next Year
- IFRX $6,309.47
- PVL N/A
- P/E Ratio
- IFRX N/A
- PVL $21.29
- Revenue Growth
- IFRX 30.90
- PVL N/A
- 52 Week Low
- IFRX $0.71
- PVL $1.11
- 52 Week High
- IFRX $2.82
- PVL $2.00
- Technical
- Relative Strength Index (RSI)
- IFRX 37.43
- PVL 53.83
- Support Level
- IFRX $0.78
- PVL $1.80
- Resistance Level
- IFRX $0.83
- PVL $1.87
- Average True Range (ATR)
- IFRX 0.04
- PVL 0.08
- MACD
- IFRX 0.03
- PVL -0.02
- Stochastic Oscillator
- IFRX 52.00
- PVL 35.71
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production the sale of oil and natural gas production from primarily non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.